Infectious Disease Alert
RSSArticles
-
Updated Management of Malaria
Malaria is preventable and treatable, yet there still are hundreds of millions of cases of malaria each year. New guidelines encourage personal and community prevention. Treatment usually is with artemisinin-based combination therapy.
-
Who Can Get the Janssen/J&J (Non-mRNA) COVID-19 Vaccine Now?
The Food and Drug Administration recently limited the use of the Janssen COVID-19 vaccine.
-
Oral Tebipenem: A New Antibiotic for Multidrug-Resistant, Gram-Negative Complicated Urinary Tract Infections
A randomized clinical trial that compared oral tebipenem with intravenous ertapenem in patients with complicated urinary tract infection or acute pyelonephritis found tebipenem to be noninferior in efficacy. The safety profile was similar between the two drugs.
-
International Outbreak of Acute Hepatitis in Children — Putative Role of Adenovirus 41
Cases of acute hepatitis in children, tentatively ascribed to adenovirus 41 infection, while first reported from a single hospital in Alabama, are being seen internationally.
-
Infectious Disease Alert Updates
Recovering from Critical COVID; Oral and Anal Transmission of Syphilis
-
A Case of Monkeypox in a Returned Traveler
The arrival of a traveler from Nigeria to the United States with monkeypox infection, which was quickly recognized, led to a massive public health response investigating exposed individuals, but no secondary cases were detected.
-
Maribavir (Livtencity)
The FDA approved maribavir as the first drug to treat adult and pediatric patients with post-transplant cytomegalovirus infections that do not respond to currently available antiviral treatment.
-
Persistent Inflammation and Post-COVID Syndrome
Ongoing inflammation may contribute to long COVID.
-
Immunosuppressants and the Risk for Clostridioides difficile Infection
A retrospective cohort study found that for patients taking immunosuppressing medications, the greatest risk for C. difficile infection occurred for those receiving calcineurin inhibitors and those taking drugs from multiple immunosuppressant classes.
-
Aminoglycoside-Induced Ototoxicity: Test Before You Treat?
Mitochondrially inherited, aminoglycoside-induced ototoxicity can cause irreversible hearing loss. Approximately 0.2% of the population is at risk, and new point-of-care genetic testing could prompt avoidance of aminoglycoside use without undue delay in antibiotic administration.